MiMedx Group Inc (MDXG) Stock AnalysisMDXGMiMedx Group Inc

MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

MiMedx Group Inc (MDXG) is a good buy right now, trading at $4.50 with a forward P/E of 19.53, which is relatively low compared to its growth potential. The recent acquisition of Sanara MedTech is expected to enhance revenue visibility and drive future growth, aiming for over $400 million in revenue by 2027. However, the company reported a net income loss of $14.84 million in Q2 2026, which poses a risk to profitability in the short term.

4 analysts cover MDXG: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.75.